CASE COMMENTS: UNILATERAL PRACTICES - RELEVANT PRODUCT MARKET - DOMINANT POSITION - PHARMACEUTICAL SECTOR

Dominant position: The French Competition Authority dismisses charges in the cetirizine tablets case for lack of dominant position after a detailed analysis of the market definition (UCB pharma)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. – Aut. conc. dec. no. 10-D-37 of 17 December 2010 concerning practices implemented on the cetirizine tablet market Under French law, the pharmaceutical sector is under the active surveillance of the competition authorities and is today one of the privileged areas of application (or attempted application) of the rules on abuse of a dominant position. This is the third decision issued by the Competition Authority ("the Authority") in this sector since its creation in 2009, the other two decisions also concern alleged abuses of dominant [1]position . At the European level, following the adoption by the Commission of its final sector inquiry report in 2009,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Wachsmann, Bastien Thomas, Dominant position: The French Competition Authority dismisses charges in the cetirizine tablets case for lack of dominant position after a detailed analysis of the market definition (UCB pharma), 17 December 2010, Concurrences N° 1-2011, Art. N° 34137, pp. 113-114

Visites 1104

All reviews